JM Financial initiates a Buy call on OneSource Specialty Pharma, setting a target price of Rs 2,049, driven by its unique CDMO positioning after consolidating Stelis and other businesses. The company is poised to benefit significantly from the rising demand for generic GLP-1s, projecting substantial revenue growth in the coming years.